<DOC>
	<DOCNO>NCT01316406</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy ATH008 cream patient Palmar-Plantar Erythrodysesthesia Syndrome ( PPES ) secondary capecitabine therapy . In part I , safety plasmatic level active ingredient metabolite allow determine appropriate beneficial dose second part study . In Part II , efficacy ATH008 cream reduce number patient present PPES grade 2/3 secondary capecitabine therapy follow four time daily application test .</brief_summary>
	<brief_title>Safety Efficacy Placebo Controlled Study ATH008 Cream PPES Patients Secondary Capecitabine</brief_title>
	<detailed_description>This Phase II Placebo Controlled , Multicenter Study involve 114 patient Palmar-Plantar Erythrodysesthesia Syndrome ( PPES ) secondary capecitabine therapy . Eligible patient enrol Part I Part II study . The first part study ( Part I ) design - demonstrate safety ATH008 cream 1 % , 3 % 8 % ATH008 cream placebo , - determine plasmatic level active ingredient metabolite repeat dos ATH008 cream 1 % , 3 % 8 % , - determine grade PPES Day 1 Day 21 ATH008 cream treatment Part I four different arm ; patient receive one three different dos drug product ( ATH008 cream 1 % , ATH008 cream 3 % ATH008 cream 8 % ) placebo ( ATH008 cream placebo ) repeat dos ( twice daily ) period 21 day . Patients continue assess safety pharmacokinetics active ingredient metabolite ( Pre-dose , Day 1 Day 21 ) . Results Part I determine appropriate beneficial dose second part study . The second part study ( Part II ) aim demonstrate safety efficacy ATH008 cream reduce number patient present PPES grade 2/3 secondary capecitabine therapy follow four time daily application . Part II three different arm ; patient receive ATH008 cream 3 % , 8 % placebo repeat dos ( four time per day ) since appearance PPES grade 1 appearance grade 2-3 maximum 4 cycle . Patients continue assess safety . The clinical sign report iconographic register lesion pain evaluated use pain scale . Patient fill questionnaire reporting QoL .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Are capecitabine monotherapy treatment colon breast cancer regimen 2 week 1 week ( 14+7 ) daily dose 2000 2500 mg/m2 . Diagnosis PPES grade 1 hand foot accord NCI CTCAE v4.03 definition . In Part I , subject still undergo least 1 planned cycle capecitabine monotherapy . In Part II , subject still undergo least 2 planned cycle capecitabine monotherapy . Are young 18 year . Use chemotherapy treatment cancer except trastuzumab ( Herceptin® ) bevacizumab ( Avastin® ) . Diagnosis PPES grade 1 hand foot accord NCI CTCAE v4.03 definition 2 cycle previously inclusion clinical study . Have neurologic symptom great grade 1 , criterion clinician could interfere PPES diagnosis study treatment ( e.g . hand foot neuropathy ) . Have dermatologic condition opinion investigator may affect hand foot may complicate evaluation study treatment ( e.g . neurodermatitis , psoriasis , etc ) . Have onycholysis nonstable grade 1 onycholysis great grade 1 ( nail loss , NCI CTCAE v4.03 criterion ) assessment clinician could interfere PPES diagnosis study treatment . Need use emollient cream topical treatment hand and/or foot study . Are receive radiotherapy . Have receive topical corticosteroid hand foot 7 day prior plan inclusion study . Are participate investigational study treatment PPES . Have participate investigational study treatment PPES , receive experimental therapeutic procedure , consider potentially interfere study 4 week precede Day 1 . The complete list eligibility criterion . Please see study doctor information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>treatment</keyword>
	<keyword>PPES</keyword>
	<keyword>Palmar-Plantar Erythrodysesthesia Syndrome</keyword>
	<keyword>Hand-foot syndrome</keyword>
	<keyword>capecitabine</keyword>
</DOC>